Intensity Therapeutics (INTS) Q2 FY26 earnings call

Intensity Therapeutics reported Q2 FY26 results highlighting significant clinical progress with the resumption of both its Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 studies, supported by improved cash flow from opportunistic ATM facility utilization. The company is actively pursuing partnerships to accelerate program advancement, while navigating funding requirements for full study expansion and managing regulatory complexities in Europe. Early clinical data from INVINCIBLE-4 shows promising pCR rates and a trend towards reduced adverse events.